Literature DB >> 3024863

Converting-enzyme inhibition and coronary blood flow.

F Magrini, M Shimizu, N Roberts, F M Fouad, R C Tarazi, A Zanchetti.   

Abstract

The effects of converting-enzyme inhibition (25 mg oral captopril) on coronary hemodynamics in the presence and absence of activation of the renin-angiotension system were studied in 10 patients with mild essential hypertension with no evidence of ischemic heart disease. Coronary blood flow was determined by thermodilution before and after 1 week of diuretic therapy in six patients and before and after placebo in four patients. The diuretic (50 mg/day furosemide) reduced coronary blood flow and increased coronary vascular resistance; in these same patients, captopril reduced mean arterial pressure and the rate-pressure product but increased coronary flow significantly. There was no change in any of these variables after captopril in the placebo group. Similar results were obtained in normotensive rats treated with hydrochlorothiazide; the increase in coronary flow after captopril correlated significantly with the control plasma renin activity. These results in hypertensive humans and normotensive experimental animals indicate that diuretic therapy reduces coronary blood flow significantly, and angiotensin can play a significant role in modulating coronary vascular resistance under conditions associated with activation of the renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3024863

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

Review 1.  The renin-angiotensin system and coronary vasomotion.

Authors:  G Ertl; K Hu; W R Bauer; B Bauer
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 2.  Regulation of Coronary Blood Flow.

Authors:  Adam G Goodwill; Gregory M Dick; Alexander M Kiel; Johnathan D Tune
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

Review 3.  Systemic and regional haemodynamic profile of diuretics and alpha- and beta-blockers. A review comparing acute and chronic effects.

Authors:  A Mimran; G Ducailar
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 4.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

5.  Effects of lisinopril on congestive heart failure in normotensive patients with diastolic dysfunction but intact systolic function.

Authors:  C C Lang; H M McAlpine; N Kennedy; A R Rahman; B J Lipworth; A D Struthers
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

6.  Coronary vasodilation induced by captopril and zofenoprilat: evidence for a prostaglandin-independent mechanism.

Authors:  J van Wijngaarden; R A Tio; W H van Gilst; P A de Graeff; C D de Langen; H Wesseling
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

Review 7.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

Review 8.  The Captopril-Digoxin Multicenter Research Group study on the comparative steps of captopril and digoxin in patients with mild-moderate heart failure: implications for therapy.

Authors:  B Pitt; S Goldstein
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

Review 9.  Role of Kinins in Hypertension and Heart Failure.

Authors:  Suhail Hamid; Imane A Rhaleb; Kamal M Kassem; Nour-Eddine Rhaleb
Journal:  Pharmaceuticals (Basel)       Date:  2020-10-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.